Biodesix to Participate in Two February Conferences

Rhea-AI Summary

Biodesix, a diagnostic solutions leader focused on lung disease, announced participation in two major conferences. The BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference will take place from February 17-19, 2021, featuring a fireside chat on February 17 at 4:00 PM ET. Additionally, Biodesix will participate in the LifeSci Partners Precision Oncology Day on the same date, hosting a panel on diagnostic sequencing at 12:00 PM ET. Biodesix continues to innovate in diagnostic testing, leveraging AI to enhance patient care.

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that management will participate in two upcoming conferences: the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which is being held February 17-19, 2021, and the LifeSci Partners Precision Oncology Day, which is being held February 17, 2021.

Event Details:

Event:			BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Format:			Fireside chat
Date:			Wednesday, February 17
Time:			4:00pm ET
Event:			LifeSci Partners Precision Oncology Day
Format:			Panel discussion on diagnostic sequencing for the treatment of cancer patients
Date:			Wednesday, February 17
Time:			12:00pm ET

About Biodesix

Biodesix is a leading diagnostic company with a focus in lung disease. The Company develops diagnostic tests addressing important clinical questions by combining multi-omics through the power of artificial intelligence. Biodesix is the first company to offer six non-invasive tests for patients with diseases of the lung. Biodesix launched the SARS-CoV-2 ddPCR™ test and the Platelia SARS-CoV-2 Total Ab in response to the global pandemic and virus that impacts the lung and causes COVID-19. The blood based Biodesix Lung Reflex® strategy for lung cancer patients integrates the GeneStrat® and VeriStrat® tests to support treatment decisions with results in 72 hours, expediting time to treatment. The blood based Nodify Lung™ nodule risk assessment testing strategy, consisting of the Nodify XL2® and the Nodify CDT™ tests, evaluates the risk of malignancy in incidental pulmonary nodules, enabling physicians to better triage patients to the most appropriate course of action. Biodesix also collaborates with many of the world’s leading biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease. For more information about Biodesix, visit biodesix.com.

Note Regarding Forward-Looking Statements

This press release may contain forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical fact, are forward-looking statements. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “plan,” “expect,” “predict,” “potential,” “opportunity,” “goals,” or “should,” and similar expressions are intended to identify forward-looking statements. Such statements are based on management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors. Biodesix has based these forward-looking statements largely on its current expectations and projections about future events and trends. These forward-looking statements are subject to a number of risks, uncertainties and assumptions. Forward-looking statements may include information concerning the impact of the COVID-19 pandemic on Biodesix and its operations, it is possible or assumed future results of operations, including descriptions of its revenues, profitability, outlook and overall business strategy. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Factors that could cause actual results to differ materially from those contemplated in this press release can be found in the Risk Factors section of Biodesix’s most recent quarterly report on Form 10Q, filed December 10, 2020. Biodesix undertakes no obligation to revise or publicly release the results of any revision to such forward-looking statements, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210212005125/en/

FAQ

When will Biodesix participate in the BTIG Virtual Conference?

Biodesix will participate in the BTIG Virtual MedTech Conference from February 17-19, 2021, with a fireside chat on February 17 at 4:00 PM ET.

What is the schedule for the LifeSci Partners Precision Oncology Day?

The LifeSci Partners Precision Oncology Day will take place on February 17, 2021, with Biodesix hosting a panel discussion at 12:00 PM ET.

What is Biodesix's focus in the diagnostic industry?

Biodesix focuses on lung disease diagnostics, developing multi-omics tests that assist in clinical decision-making.

What innovative tests has Biodesix launched recently?

Biodesix launched the SARS-CoV-2 ddPCR™ test and Platelia SARS-CoV-2 Total Ab in response to the COVID-19 pandemic.

What is the ticker symbol for Biodesix?

Biodesix trades under the ticker symbol BDSX on Nasdaq.